mani
virus
tropism
cell
respiratori
tract
infect
virus
caus
sporad
sometim
seriou
outbreak
may
lead
signific
morbid
mortal
transmiss
virus
human
may
occur
result
crossspeci
spread
anim
swine
bird
case
influenza
viru
spread
virus
individu
usual
result
inhal
viruscontain
droplet
contact
contamin
object
effici
transmiss
make
control
infect
difficult
achiev
especi
contain
outbreak
delay
spread
respiratori
virus
may
rapid
area
dens
popul
infect
individu
direct
close
contact
mani
peopl
case
initi
outbreak
pandem
caus
infect
sever
acut
respiratori
syndrom
sar
coronaviru
cov
healthcar
worker
treat
infect
individu
turn
respons
wider
spread
viru
peopl
gaundong
provinc
china
hypermut
virus
lead
signific
chang
properti
sometim
new
viral
strain
emerg
seriou
patholog
effect
high
rate
mutat
may
also
account
abil
virus
spread
one
speci
anoth
variabl
viral
gene
sequenc
express
complic
manag
thwart
develop
effect
vaccin
treatment
therefor
avail
expertis
may
rapidli
ration
deploy
counter
epidem
respiratori
viral
infect
would
valuabl
gene
therapi
provid
resourc
purpos
virus
caus
respiratori
infect
genom
compris
rna
gene
silenc
antisens
approach
favor
disabl
viral
replic
deliveri
antivir
nucleic
acid
infect
tissu
facilit
anatomi
pulmonari
system
intranas
intratrach
administr
therapeut
may
conveni
use
distribut
candid
drug
infect
cell
signific
progress
made
use
nucleic
acid
treat
viral
infect
gene
therapi
well
posit
advanc
clinic
use
treatment
respiratori
viral
infect
respiratori
syncyti
viru
rsv
member
famili
paramyxovirida
pneumoviru
genu
review
ref
virion
variabl
spheric
shape
rang
nm
diamet
viral
capsid
envelop
bud
process
releas
viral
particl
infect
cell
name
viru
deriv
observ
infect
cell
becom
fuse
form
syncytia
two
antigen
subtyp
viru
b
infect
subtyp
b
common
associ
milder
symptom
infect
rsv
acquir
close
contact
respiratori
secret
infect
person
may
also
transmit
contact
contamin
object
rsv
infect
preval
throughout
world
major
caus
season
lower
respiratori
infect
young
children
estim
almost
children
infect
rsv
time
reach
year
age
sever
infect
usual
depend
age
seriou
infant
young
children
inher
narrow
airway
young
children
exacerb
mucos
swell
associ
infect
contribut
particularli
restrict
air
flow
tracheobronchi
tree
younger
age
group
elderli
patient
adult
bone
marrow
transplant
recipi
infect
rsv
may
also
experi
signific
morbid
evid
indic
rsv
infect
typic
occur
children
previous
healthi
howev
prophylact
treatment
may
implement
prevent
complic
certain
group
young
children
thought
high
risk
seriou
clinic
cours
congenit
heart
defect
exposur
infect
usual
manifest
day
overal
durat
approxim
week
small
proport
infect
children
bronchiol
may
develop
carri
risk
asthma
later
life
immun
viru
durabl
therefor
individu
suscept
multipl
infect
lifetim
occur
older
children
adult
rsv
infect
typic
restrict
upper
respiratori
tract
progress
made
vaccin
develop
wide
avail
prophylact
immunogen
current
avail
treatment
infect
individu
mainli
support
aim
improv
pulmonari
air
flow
rsv
genom
compris
rna
strand
approxim
kb
neg
strand
polar
kilobas
figur
eleven
protein
encod
includ
structur
nonstructur
sequenc
virion
contain
three
surfac
glycoprotein
attach
g
fusion
f
sh
protein
act
concert
fuse
particl
respiratori
epitheli
membran
deliv
rna
genom
replic
express
viral
protein
helic
capsid
form
nucleocapsid
n
protein
bind
protect
rna
genom
nonstructur
ns
protein
includ
respiratori
syncyti
viru
larg
polymeras
subunit
l
phosphoprotein
p
respons
inhibit
host
innat
immun
respons
infect
viru
togeth
nonstructur
protein
l
p
compon
enabl
replic
viral
genom
regul
express
viral
gene
rsv
prolifer
restrict
respiratori
epitheli
cell
use
deliveri
therapeut
nucleic
acid
target
viru
sever
studi
report
util
rna
interfer
rnai
activ
effect
inhibit
rsv
replic
first
studi
perform
cell
cultur
model
rsv
infect
demonstr
success
inhibit
viral
replic
small
interf
rna
sirna
target
p
f
sequenc
figur
followup
investig
confirm
efficaci
vivo
use
mice
simul
human
rsv
infect
sirna
effect
administ
nake
nucleic
acid
formul
transfect
reagent
marker
viral
replic
suppress
indic
bronchoconstrict
diminish
without
evid
nonspecif
activ
interferon
respons
anoth
studi
report
effect
inhibit
rsv
replic
mice
administr
express
cassett
administ
intranas
within
chitosancontain
nanoparticl
chapter
antivir
efficaci
accompani
diminish
inflamm
reactiv
airway
singlestrand
rna
antisens
polar
compris
kb
plu
strand
deriv
genom
use
translat
templat
synthesi
indic
viral
protein
intergen
sequenc
viral
orf
leader
trailer
sequenc
end
genom
translat
site
within
genom
success
target
use
rnai
activ
indic
efficaci
report
zhang
colleagu
character
devincenzo
et
al
rsvp
rsvf
silenc
develop
bitko
et
al
advanc
gene
therapi
treatment
rsv
infect
progress
stage
test
clinic
trial
alnylam
pharmaceut
develop
use
ntarget
lead
synthet
sirna
call
administ
patient
nasal
spray
treatment
well
toler
without
evid
side
effect
antivir
efficaci
demonstr
healthi
adult
volunt
receiv
inoculum
viru
followup
studi
perform
rsvinfect
patient
receiv
lung
transplant
http
although
primari
endpoint
reduc
bronchiol
obliteran
syndrom
met
intenttotreat
analysi
therapeut
effect
observ
influenza
acut
respiratori
infect
caus
virus
belong
orthomymyxovirida
famili
three
genera
famili
influenzaviru
influenzaviru
b
influenzaviru
c
influenzaviru
genu
one
speci
influenzaviru
viru
natur
infect
rang
speci
especi
migratori
aquat
bird
may
transmit
anim
human
influenza
viru
also
virul
caus
sporad
pandem
outbreak
signific
mortal
morbid
recent
review
ref
sever
serotyp
influenza
viru
base
presenc
particular
epitop
within
hemagglutinin
ha
neuraminidas
na
protein
locat
surfac
viral
particl
figur
eight
rna
segment
influenza
viru
compris
strand
neg
polar
complex
viral
nucleoprotein
np
protein
polymeras
complexpa
also
associ
viral
genom
nep
locat
within
lipid
envelop
abund
ha
na
protein
expos
surfac
viral
particl
ion
channel
protein
play
role
mediat
endosom
escap
viral
entri
cell
also
embed
lipid
envelop
influenza
viru
serotyp
name
accord
particular
epitop
character
pathogen
virus
exampl
serotyp
viru
respons
outbreak
spanish
flu
swine
flu
asian
flu
pandem
caus
serotyp
viru
may
transmit
inhal
influenza
viru
acontain
aerosol
direct
contact
viruscontamin
surfac
howev
influenza
viru
inactiv
standard
hygien
wash
practic
direct
exposur
sunlight
approxim
individu
expos
viru
becom
symptomat
symptom
occur
nonspecif
includ
headach
fever
gener
bodi
pain
fatigu
nasal
congest
upper
respiratori
tract
symptom
viral
particl
influenza
viru
typic
spheric
envelop
review
ref
figur
genom
segment
compris
eight
singlestrand
rna
molecul
neg
polar
figur
viral
sequenc
prone
mutat
genet
chang
result
reassort
genom
segment
factor
contribut
variabl
viral
protein
antigen
drift
sometim
propens
viru
caus
crossspeci
infect
outbreak
pandem
reassort
influenza
genom
occur
one
viru
infect
cell
segment
packag
individu
viral
particl
differ
combin
packag
virion
viral
particl
acquir
new
properti
may
influenc
host
rang
diseas
pathogenesi
eight
segment
influenza
genom
largest
kb
smallest
nt
encod
polymeras
polymeras
polymeras
pa
ha
nucleoprotein
np
na
matrix
nonstructur
nuclear
export
protein
nep
protein
figur
total
size
genom
approxim
kb
infect
cell
neg
strand
convert
posit
strand
crnamrna
viral
rna
polymeras
cap
snatch
cellular
mrna
stutter
viral
polymeras
stretch
u
residu
end
genom
segment
result
modif
posit
strand
resembl
eukaryot
mrna
altern
splice
read
frame
shift
viral
mrna
increas
number
protein
may
express
influenza
viru
genom
exampl
protein
translat
altern
splice
mrna
deriv
segment
viral
genom
depend
strain
protein
may
express
viru
uptak
influenza
viru
cell
mediat
interact
ha
viral
particl
sialic
acid
receptor
cell
surfac
clathrinmedi
endocytosi
releas
endosom
nuclear
transport
follow
reach
endosom
protein
function
phgate
proton
channel
caus
acidif
interior
virion
result
dissoci
ribonucleoprotein
complex
transport
genom
segment
nucleu
replic
viral
genom
format
translat
templat
occur
nucleu
accumul
matrix
protein
ribonucleoprotein
complex
lead
export
cytoplasm
facilit
nep
thereaft
bud
occur
releas
newli
form
viral
particl
na
requir
matur
virion
function
cleav
cellular
sialic
acid
receptor
molecul
figur
eight
segment
collect
make
genom
influenza
viru
togeth
site
target
use
gene
silenc
segment
revers
complement
serv
mrna
size
encod
protein
indic
addit
protein
shown
illustr
may
also
gener
segment
result
altern
translat
initi
shift
read
frame
site
target
studi
aim
develop
use
gene
therapi
inhibit
replic
viru
indic
arrowhead
sirna
target
pa
pa
np
np
sequenc
describ
ge
et
al
tompkin
colleagu
stewart
et
al
shrna
antivir
rnai
activ
describ
li
et
al
provid
protect
mice
lethal
exposur
influenza
viru
express
sequenc
effect
viral
replic
deliv
recombin
lentivir
vector
case
number
refer
nucleotid
coordin
viral
segment
target
rnai
activ
influenza
viru
viral
particl
facilit
releas
newli
form
virion
defici
na
restrict
replic
viru
enzym
target
import
class
antivir
drug
vaccin
influenza
viru
remain
prefer
mode
protect
ill
viru
compon
vaccin
regularli
deriv
recent
isol
strain
viru
vaccin
recommend
administr
peopl
older
month
age
licens
drug
treatment
influenza
infect
fall
two
broad
categori
inhibitor
viral
na
inhibitor
protein
review
ref
na
inhibitor
act
interf
bud
matur
virion
infect
cell
see
section
current
licens
na
inhibitor
oseltamivir
zanamivir
inhibitor
deriv
adamantan
amantadin
rimantadin
function
prevent
endosom
releas
virion
infect
cell
inhibitor
associ
toxic
emerg
mutant
escap
effect
drug
na
inhibitor
provid
high
barrier
viral
resist
gener
well
toler
although
evid
benefici
effect
treatment
administ
earli
infect
influenza
viru
studi
indic
favor
effect
treatment
minim
evid
indic
rnai
pathway
serv
antivir
mechan
host
cell
influenza
viru
howev
viru
may
counter
antivir
effect
host
gene
silenc
effect
protein
although
effect
disput
effect
appear
vari
depend
strain
viru
despit
possibl
inhibitori
effect
influenza
viru
rnai
sever
studi
shown
gene
silenc
effect
influenza
viru
ge
colleagu
report
inhibit
viral
gene
express
use
synthet
sirna
sever
differ
site
target
greatest
efficaci
shown
sirna
cognat
within
pa
np
region
figur
efficaci
demonstr
madindarbi
canin
kidney
mdck
cell
transfect
sirna
infect
isol
influenza
viru
good
inhibit
viral
replic
also
observ
infect
embryon
chicken
egg
interest
observ
sirna
particularli
effect
crnamrna
sequenc
littl
effect
neg
strand
genom
segment
specif
particular
viral
rna
strand
may
result
bia
occur
process
duplex
sirna
addit
presenc
crnamrna
cytoplasm
diminish
access
npprotect
genom
segment
rnai
machineri
may
contribut
strand
select
li
et
al
recent
confirm
sequenc
good
target
site
inhibit
influenza
viru
replic
use
express
rnai
activ
short
hairpin
rna
shrna
followup
studi
ge
colleagu
evalu
efficaci
sirna
virusinfect
mice
sirna
complex
polyethylin
imin
intraven
administ
signific
antivir
effect
observ
gene
silenc
administ
exposur
sirna
given
viral
infect
establish
mice
studi
show
express
rnai
activ
also
activ
viral
replic
cultur
cell
deliv
recombin
lentivir
vector
use
lentivir
vector
deliv
influenza
viru
atarget
shrna
describ
studi
silenc
sequenc
effect
inhibit
replic
viru
mdck
cell
evid
escap
mutant
emerg
longterm
suppress
addit
gene
silenc
effect
avian
strain
viru
tompkin
et
al
util
sirna
target
site
pa
np
administ
gene
silenc
formul
commerci
avail
transfect
reagent
antivir
sequenc
activ
differ
viral
isol
protect
mice
lethal
challeng
highli
pathogen
strain
influenza
viru
suppress
viral
replic
cultur
cell
mice
also
demonstr
studi
describ
use
sirna
target
pa
sequenc
viru
particular
sirna
provid
protect
viru
suzuki
colleagu
use
bicistron
express
cassett
target
np
sequenc
influenza
influenza
b
virus
inhibit
replic
virus
demonstr
cultur
cell
cassett
also
effect
use
recombin
baculoviru
vector
np
sequenc
target
zhou
colleagu
studi
perform
mdck
cell
mice
effect
suppress
isol
demonstr
activ
innat
immun
respons
duplex
rna
also
investig
mean
inhibit
influenza
viru
stewart
et
al
show
posit
ugugu
sequenc
end
sens
strand
sirna
target
augment
antivir
efficaci
although
interest
approach
util
verifi
cultur
cell
avoid
inadvert
unintend
effect
vivo
may
difficult
achiev
influenza
viru
predispos
mutat
develop
gene
silenc
methodolog
prevent
escap
import
addit
use
combinatori
rnai
silenc
host
factor
requir
viru
replic
may
also
use
highthroughput
screen
studi
report
karla
colleagu
enabl
identif
human
host
factor
howev
investig
use
silenc
host
factor
therapeut
applic
yet
thoroughli
explor
use
antisensebas
methodolog
inhibit
replic
highli
pathogen
avian
strain
influenza
viru
demonstr
sar
cov
chicken
rna
oligonucleotid
target
ha
sequenc
formul
commerci
avail
transfect
reagent
administ
airway
bird
three
dose
antisens
formul
effect
protect
chicken
viru
recent
posit
charg
phosphorodiamid
morpholino
oligonucleotid
also
use
treat
influenza
viru
infect
candid
drug
clinic
stage
evalu
sarepta
therapeut
http
wwwsareptacom
pipelin
overal
good
efficaci
variou
influenza
viru
atarget
nucleic
acid
demonstr
cultur
cell
vivo
howev
studi
yet
progress
beyond
evalu
small
anim
model
import
implement
prompt
therapeut
intervent
emerg
pathogen
emphas
outbreak
sar
case
initi
report
asia
rapid
spread
infect
part
world
approxim
peopl
affect
approxim
death
result
epidem
mortal
high
peopl
age
year
unexplain
reason
mortal
low
children
younger
year
caus
agent
rapidli
identifi
cov
name
sarscov
speci
member
coronavirida
famili
coronaviru
genu
virus
genu
transmiss
across
speci
may
infect
mani
differ
anim
caus
diseas
review
ref
pleomorph
virion
envelop
figur
contain
singlestrand
rna
genom
posit
polar
compris
figur
schemat
illustr
structur
viral
particl
sarscov
singlestrand
rna
genom
complex
n
protein
turn
locat
within
membran
envelop
e
glycoprotein
embed
envelop
circular
structur
crosssect
protrud
protein
give
virion
characterist
crownlik
appear
view
use
transmiss
electron
microscopi
approxim
kb
figur
discoveri
genom
viru
character
remark
speed
provid
basi
ration
design
gene
therapybas
approach
counter
sarscov
cov
sarscov
crownlik
coron
appear
view
use
transmiss
electron
microscopi
spike
glycoprotein
embed
viral
envelop
form
protrus
give
characterist
appear
virion
figur
initi
entri
viru
cell
infect
interact
human
angiotensin
convert
two
glycoprotein
also
posit
envelop
membran
envelop
e
protein
nucleocapsid
protein
n
respons
packag
viral
genom
helic
arrang
viral
open
read
frame
orf
encod
polyprotein
refer
function
viral
replicas
sequenc
compris
twothird
genom
figur
translat
genom
rna
rapidli
convert
genom
rna
minu
strand
turn
lead
format
nest
subgenom
mrna
serv
singlestrand
rna
sens
polar
compris
kb
sequenc
flank
utr
interven
sequenc
encod
viral
structur
nonstructur
protein
larg
orf
encod
polyprotein
process
gener
nonstructur
protein
requir
replic
viral
genom
four
structur
gene
e
n
encod
spike
envelop
membran
nucleocapsid
protein
respect
eight
accessori
protein
encod
orf
overlap
within
quarter
genom
select
site
within
genom
success
target
use
rnai
activ
indic
efficaci
report
li
colleagu
character
wang
et
al
silenc
develop
zhang
et
al
approxim
coordin
first
nucleotid
cognat
gene
silenc
guid
indic
parenthes
utr
untransl
region
sar
cov
translat
templat
synthesi
viral
protein
synthesi
occur
translat
read
frame
shift
orf
sequenc
matur
follow
proteolyt
cleavag
perform
viral
chymotrypsinlik
proteas
papainlik
proteas
eight
accessori
protein
encod
viru
essenti
replic
viru
cultur
cell
review
ref
function
includ
regul
program
cell
death
cell
signal
control
innat
immun
respons
suppress
releas
proinflammatori
cytokin
name
indic
infect
sarscov
character
rapid
onset
sever
respiratori
symptom
individu
infect
viru
contagi
viru
affect
lower
respiratori
tract
properti
facilit
restrict
spread
sarscov
identif
infecti
individu
placement
quarantin
transmiss
viru
occur
result
droplet
spread
although
respiratori
tract
primari
site
infect
viru
may
also
spread
organ
gastrointestin
tract
pathogenesi
diseas
primarili
occur
result
host
immun
respons
infect
correl
observ
symptom
becom
wors
clearanc
viru
epidem
aros
like
origin
crossspeci
spread
palm
civet
handler
work
market
sell
anim
howev
chines
horsesho
bat
implic
primari
reservoir
viru
anim
like
transmit
viru
mammalian
speci
infect
human
effect
treatment
sarscov
infect
good
vaccin
har
gene
therapi
counter
infect
logic
line
investig
swift
detail
character
sarscov
genom
enabl
rapid
develop
potenti
therapeut
anti
sarscov
rnai
activ
figur
although
none
investig
progress
clinic
trial
proof
principl
demonstr
use
variou
cell
cultur
model
simul
human
infect
addit
speed
candid
nucleic
acid
therapeut
identifi
reinforc
notion
ration
design
use
gene
therapi
may
power
mean
rapidli
advanc
treatment
emerg
pathogen
wang
colleagu
initi
report
use
express
cassett
gener
six
antivir
rnai
activ
target
variou
site
within
genom
lead
antivir
cognat
orf
sequenc
figur
inhibit
viral
replic
attenu
cytopath
effect
demonstr
cultur
vero
cell
deriv
african
green
monkey
subsequ
studi
also
perform
vero
cell
demonstr
efficaci
synthet
sirna
viru
particularli
good
inhibit
viral
replic
demonstr
sirna
target
sequenc
gene
also
shown
good
target
inhibit
sarscov
cultur
cell
express
rnai
activ
advanc
studi
use
rnai
sarscov
assess
efficaci
synthet
sirna
sarscov
nonhuman
primat
rnai
activ
cognat
orf
region
viral
genom
develop
candid
drug
short
duplex
dtdt
overhang
end
otherwis
unmodifi
initi
assess
murin
model
infect
follow
evalu
rhesu
macaqu
sirna
administ
dextros
solut
given
intranas
took
advantag
anatomi
respiratori
airway
distribut
sirna
sarscovinfect
cell
treatment
effect
inhibit
replic
sarscov
allevi
pathogenesi
virusrel
diseas
epidem
sarscov
effect
contain
death
result
infect
report
sinc
http
wwwcdcgovsar
howev
despit
success
import
lesson
outbreak
cov
potenti
seriou
pathogen
abil
virus
adapt
achiev
crossspeci
infect
particularli
concern
may
seriou
outbreak
infect
caus
virus
coronavirida
famili
inde
emerg
middl
east
respiratori
syndrom
mer
also
caus
cov
support
notion
problem
relat
infect
mer
viru
widespread
sever
caus
sarscov
nevertheless
vigil
advanc
technolog
would
abl
deal
event
import
insight
gain
use
rnai
sarscov
valuabl
use
advanc
treatment
respiratori
coronavir
infect
feasibl
gene
therapi
treatment
respiratori
viral
infect
measl
viru
parainfluenza
viru
also
explor
har
rnai
popular
strategi
inhibit
express
viral
gene
silenc
host
depend
factor
virus
requir
replic
review
ref
exampl
develop
rnaibas
treatment
measl
viru
infect
despit
widespread
vaccin
program
effect
prevent
infect
viru
diseas
relat
transmiss
measl
viru
remain
import
global
problem
modest
efficaci
avail
drug
ribavirin
prompt
investig
gene
therapi
treat
infect
synthet
express
rnai
activ
target
viral
mrna
contain
l
sequenc
respons
encod
essenti
viral
rnadepend
rna
polymeras
use
conclus
inhibit
viral
replic
cultur
cell
effect
observ
without
evid
toxic
recent
investig
verifi
good
silenc
viral
replic
could
achiev
gene
silenc
cognat
viral
sequenc
measl
viru
receptor
signal
lymphocyt
activ
molecul
gtpase
essenti
host
factor
requir
replic
viru
also
effect
silenc
counter
measl
viru
replic
addit
viral
gene
host
factorencod
gene
silenc
togeth
attempt
augment
antivir
efficaci
although
approach
demonstr
impress
result
show
potenti
therapeut
applic
feasibl
implement
gene
therapi
measl
viru
infect
like
face
sever
challeng
moreov
avail
effect
vaccin
acut
natur
measl
viru
infect
suggest
gene
therapi
prioriti
treat
diseas
virus
caus
infect
respiratori
tract
common
highli
vari
origin
present
pathognomon
sign
symptom
unusu
molecular
diagnosi
immunoassay
play
import
role
diagnosi
set
resourc
limit
may
retard
identif
etiolog
agent
respons
clinic
present
compound
problem
delay
diagnosi
infect
respiratori
virus
usual
occur
rapidli
contact
respiratori
secret
infect
individu
transmiss
may
occur
individu
case
result
interspeci
infect
moreov
respiratori
virus
influenza
viru
readili
mutat
genom
gener
virus
new
properti
diseas
pathogenesi
addit
vaccin
avail
therapi
respiratori
viral
infect
often
modest
efficaci
collect
potenti
sever
respiratori
viral
infect
coupl
risk
emerg
new
strain
particularli
pathogen
strain
pose
public
health
challeng
improv
technolog
enabl
rapid
thorough
character
genom
emerg
pathogen
provid
import
inform
requir
develop
gene
therapybas
treatment
respiratori
viral
infect
respiratori
virus
rna
genom
virus
replic
cytoplasm
therapeut
strategi
base
use
antisens
rnai
activ
favor
gene
therapi
viral
infect
deliveri
antivir
nucleic
acid
challeng
howev
case
respiratori
viral
infect
anatom
structur
airway
may
exploit
administr
therapeut
nucleic
acid
inhal
solut
formul
contain
candid
drug
conveni
distribut
nucleic
acid
along
trachea
bronchi
bronchiol
alveoli
approach
use
clinic
trial
treatment
rsv
infect
result
use
inform
broader
develop
gene
therapi
infect
respiratori
virus
airway
administr
antivir
nucleic
acid
also
shown
effect
counter
influenza
viru
sarscov
anim
model
infect
persist
risk
emerg
highli
pathogen
respiratori
virus
remain
concern
lesson
learn
outbreak
sarscov
pandem
valuabl
although
knowhow
may
use
platform
treat
respiratori
viral
infect
still
develop
object
achiev
rapid
implement
effect
treatment
seem
reachabl
avail
sophist
molecular
techniqu
improv
method
disabl
viral
gene
express
eas
administr
respiratori
tract
particularli
import
advanc
gene
therapi
respiratori
viral
infect
develop
sure
contribut
significantli
effect
manag
current
emerg
pathogen
respiratori
viral
infect
futur
